The progress report on the safety and clinical efficacy of GAIA-102 against pediatric solid malignant tumors will be presented at the 66th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology

Fukuoka, JAPAN – Dr. Naonori KAWAKUBO, the principal investigator of the ‘Phase I Trial of NK Cell-like CD3-negative Cells (GAIA-102) for Recurrent and Refractory Neuroblastoma or Pediatric Solid Malignant Tumors with Lung Metastases’, conducted at the Department of Pediatric Surgery, Kyushu University, under the supervision of Professor Tatsuro Tajiri, will present the progress report on the safety and clinical efficacy of GAIA-102 against relapsed/refractory pediatric solid malignant tumors at the 66th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology.

Summary of the presentation is as follows:

Title: Safety and efficacy of CD3-Negative NK cell-like cells (GAIA-102) against relapsed/refractory pediatric solid malignant tumors
Presenter: Dr. Naonori KAWAKUBO
Session: Symposium 6: ‘Cell therapy against pediatric solid tumors’
Date and Time: December 14, 2024 (Saturday) 14:35~16:35 (JST)
Venue: Kyoto International Conference Center (2nd venue) / Streaming

Share on